Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services
Background: Long-acting injectable (LAI) antipsychotic medications are used to optimise treatment outcomes in schizophrenia. Guaranteed medication delivery increases the responsibility of prescribers to monitor and manage adverse effects. Methods: In the context of a quality improvement programme co...
Main Authors: | Carol Paton, Tom K. J. Craig, Brittany McConnell, Thomas R. E. Barnes |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Psychopharmacology |
Online Access: | https://doi.org/10.1177/2045125321991278 |
Similar Items
-
The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
by: Thomas R. E. Barnes, et al.
Published: (2020-08-01) -
Physical health monitoring after rapid tranquillisation: clinical practice in UK mental health services
by: Carol Paton, et al.
Published: (2019-12-01) -
Therapeutic drug monitoring of LAI antipsychotics as a predictor of clinical relapse: a one-year follow-up
by: G. D’Anna, et al.
Published: (2022-06-01) -
Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
by: Marcin Jarosz, et al.
Published: (2022-09-01) -
Improving the "real life" management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services.
by: Valeria Latorre, et al.
Published: (2020-01-01)